Home Drug IndexClinical Monograph

Escitalopram Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antidepressant

Subclass

Selective Serotonin Reuptake Inhibitor (SSRI)

Speciality

Psychiatry

Schedule (India)

Schedule H

Routes

Oral

Formulations

Tablets: 5 mg, 10 mg, 20 mg
Oral drops/solution: 5 mg/mL (limited availability)
Note: Fixed-dose combinations with clonazepam available — use with caution, specialist supervision preferred

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Major Depressive Disorder (MDD)

Adults:

Parameter	Recommendation
Starting dose	10 mg once daily (morning or evening)
Titration	May increase to 20 mg/day after ≥1 week if inadequate response
Usual maintenance dose	10–20 mg/day
Maximum dose	20 mg/day

Clinical notes:

Evaluate response after 4–6 weeks of adequate dosing
Continue for minimum 6–9 months after remission to prevent relapse
For recurrent depression, longer maintenance (≥2 years) may be required

2. Generalised Anxiety Disorder (GAD)

Adults:

Parameter	Recommendation
Starting dose	10 mg once daily (may start at 5 mg in sensitive patients)
Titration	Increase to 10–20 mg/day based on response after 2–4 weeks
Usual maintenance dose	10 mg/day
Maximum dose	20 mg/day

Clinical notes:

Anxiolytic effect may take 2–4 weeks to manifest
Long-term treatment often necessary; taper gradually when discontinuing

3. Panic Disorder (with or without Agoraphobia)

Adults:

Parameter	Recommendation
Starting dose	5 mg once daily for first week
Titration	Increase to 10 mg/day after 1 week; further increase to 15–20 mg/day after 1 month if needed
Usual maintenance dose	10–15 mg/day
Maximum dose	20 mg/day

Clinical notes:

Initial worsening of anxiety may occur — warn patient
Slower titration essential to improve tolerability
Cognitive behavioural therapy (CBT) recommended as adjunct

4. Obsessive-Compulsive Disorder (OCD)

Adults:

Parameter	Recommendation
Starting dose	10 mg once daily
Titration	May increase to 20 mg/day after 2–4 weeks
Usual maintenance dose	10–20 mg/day
Maximum dose	20 mg/day

Clinical notes:

Higher doses may be needed; some specialists use up to 30 mg/day (off-label, specialist only)
Long-term treatment usually required (≥1–2 years)
Consider augmentation with antipsychotics in partial responders

5. Social Anxiety Disorder (Social Phobia)

Adults:

Parameter	Recommendation
Starting dose	10 mg once daily
Titration	May increase to 20 mg/day after 2–4 weeks if needed
Usual maintenance dose	10–20 mg/day
Maximum dose	20 mg/day

Clinical notes:

Response may take 8–12 weeks for full effect
Combine with exposure therapy for optimal outcomes

Secondary Indications — Adults Only (Off-label)

Indication	Dose	Duration	Notes
Post-Traumatic Stress Disorder (PTSD) — OFF-LABEL	Starting: 10 mg/day; Max: 20 mg/day	6–12 months minimum	Specialist supervision; RCT evidence supports efficacy
Premenstrual Dysphoric Disorder (PMDD) — OFF-LABEL	10 mg/day continuously OR 10 mg/day during luteal phase (day 14–28)	Cyclical or continuous; reassess every 3–6 months	International RCT evidence; used in Indian urban psychiatric practice
Vasomotor symptoms of menopause — OFF-LABEL	10–20 mg/day	Variable	When HRT contraindicated; limited Indian data

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications

1. Major Depressive Disorder — Adolescents (12–17 years)

Parameter	Recommendation
Starting dose	5 mg once daily
Titration	May increase to 10 mg/day after 1 week
Usual maintenance dose	10 mg/day
Maximum dose	20 mg/day

Safety monitoring:

⚠️ Black box warning equivalent: Increased risk of suicidal ideation in early weeks of treatment
Weekly face-to-face review for first 4 weeks, then fortnightly for next month
Monitor for behavioural activation, agitation, self-harm ideation

Secondary Indications — Paediatrics (Off-label)

Indication	Age	Dose	Notes
OCD — OFF-LABEL	≥7 years	Children: 5 mg/day; Adolescents: 10 mg/day; Max: 20 mg/day	Specialist only; monitor for behavioural activation, sleep disturbance, weight changes
Anxiety disorders — OFF-LABEL	≥12 years	5–10 mg/day; Max: 20 mg/day	Limited Indian paediatric data; specialist supervision mandatory

Paediatric Safety Statement

⚠️ Not recommended in children <12 years for depression or <7 years for any indication except under specialist supervision with documented informed consent regarding suicide risk.

Renal Adjustments

Renal Function	Recommendation
Mild impairment (eGFR 60–89)	No adjustment required
Moderate impairment (eGFR 30–59)	No adjustment required
Severe impairment (eGFR <30)	Start at 5 mg/day; titrate cautiously
Haemodialysis	No specific data; use with caution at low doses

Hepatic adjustment

Contraindications

Known hypersensitivity to escitalopram, citalopram, or any SSRI
Concurrent use with MAO inhibitors (including moclobemide, linezolid, methylene blue) or within 14 days of MAOI discontinuation
Congenital long QT syndrome or known QT prolongation
Concurrent use with pimozide
Concurrent use with other drugs that prolong QT interval in patients with additional risk factors

Cautions

History of seizure disorder — may lower seizure threshold
Bipolar disorder — risk of manic switch; use with mood stabiliser
History of suicidal ideation or self-harm — close monitoring essential
Elderly patients — increased risk of hyponatraemia and QT prolongation
Patients at risk of bleeding (concurrent anticoagulants, NSAIDs, antiplatelet agents)
Narrow-angle glaucoma — may precipitate acute attack
Hepatic impairment — reduced clearance
Severe renal impairment
Patients with electrolyte disturbances (hypokalaemia, hypomagnesaemia)
Concomitant use of drugs affecting serotonin (risk of serotonin syndrome)

Pregnancy

Aspect	Guidance
Overall safety	Low teratogenic risk based on available data; one of the preferred SSRIs in pregnancy
First trimester	No consistent evidence of major malformations; may continue if clinically indicated
Third trimester	Risk of neonatal adaptation syndrome (jitteriness, irritability, respiratory distress, feeding difficulties)
Preferred alternatives	Sertraline generally considered first choice in Indian obstetric psychiatry; escitalopram acceptable alternative
When to use	If clear maternal benefit; untreated severe depression carries significant risks
Monitoring	Neonatal observation for 48–72 hours post-delivery if used near term

Lactation

Aspect	Guidance
Compatibility	Compatible with breastfeeding
Excretion in milk	Low (relative infant dose <5%)
Preferred alternatives	Sertraline may be preferred, especially for preterm or low-birth-weight infants
Infant monitoring	Observe for sedation, poor feeding, irritability, weight gain
Clinical note	Avoid breastfeeding at peak plasma concentration (4–6 hours post-dose) if concerns

Elderly

Aspect	Recommendation
Starting dose	5 mg once daily
Titration	Increase slowly; allow 2 weeks between dose changes
Maximum dose	10 mg/day (due to QT prolongation risk at higher doses)
Extra risks	Hyponatraemia (SIADH), QT prolongation, falls, confusion, bleeding
Monitoring	Baseline ECG if cardiac history; check sodium at baseline and periodically

Major drug interactions

Interacting Drug	Effect	Management
MAO inhibitors (phenelzine, tranylcypromine, moclobemide, linezolid, methylene blue)	Serotonin syndrome — potentially fatal	CONTRAINDICATED; wait 14 days after stopping MAOI before starting escitalopram
Pimozide	Additive QT prolongation; risk of torsades de pointes	CONTRAINDICATED
Other QT-prolonging drugs (haloperidol, amiodarone, sotalol, methadone, ondansetron)	Additive QT prolongation	Avoid combination or use with ECG monitoring
Tramadol	Serotonin syndrome risk; lowered seizure threshold	Avoid; if essential, use lowest doses with close monitoring
Triptans (sumatriptan, etc.)	Serotonin syndrome risk	Use with caution; monitor for symptoms
Lithium	Increased serotonergic effects	Use together cautiously with monitoring

Moderate drug interactionsModerate drug interactions

Interacting Drug	Effect	Management
NSAIDs (ibuprofen, diclofenac)	Increased GI bleeding risk	Use gastroprotection if chronic use; monitor
Aspirin / Antiplatelet agents	Increased bleeding risk	Monitor for bruising, bleeding
Warfarin / Acenocoumarol	Altered anticoagulant effect; increased bleeding	Monitor INR more frequently
Carbamazepine, Phenytoin	Enzyme induction — reduced escitalopram levels	Monitor clinical response; may need dose increase
Omeprazole, Cimetidine	CYP2C19 inhibition — increased escitalopram levels	Monitor for adverse effects; consider dose reduction
Alcohol	Additive CNS depression	Advise avoidance
Metoprolol	Increased metoprolol levels (CYP2D6 substrate)	Monitor for bradycardia, hypotension

Common Adverse effects

Nausea (usually transient, improves in 1–2 weeks)
Headache
Insomnia or somnolence
Dry mouth
Increased sweating
Diarrhoea or constipation
Dizziness
Fatigue
Sexual dysfunction (decreased libido, anorgasmia, delayed ejaculation) — may persist

Serious Adverse effects

Adverse Effect	Clinical Notes
QT prolongation / Torsades de pointes	Dose-dependent; higher risk at 20 mg/day and in elderly; obtain ECG if risk factors present
Serotonin syndrome	Presents with hyperthermia, rigidity, myoclonus, autonomic instability, altered mental status; discontinue immediately; supportive care
Hyponatraemia / SIADH	Especially in elderly; presents with confusion, lethargy, seizures; check sodium levels
Suicidal ideation	Particularly in adolescents/young adults in early weeks; close monitoring essential
Seizures	Rare; dose-related
Manic switch	In undiagnosed bipolar disorder; discontinue and reassess diagnosis
Abnormal bleeding	GI bleeding, ecchymoses; especially with concurrent anticoagulants/NSAIDs

Monitoring requirements

Phase	Parameters
Baseline	Mental status assessment, suicidality screening, BP, weight, serum sodium (especially elderly), ECG (if cardiac history, elderly, or QT risk factors)
Early treatment (weeks 1–4)	Weekly suicidality assessment; mood, sleep, appetite monitoring
During titration	Reassess response and tolerability at 2–4 weeks
Long-term	Serum sodium every 6–12 months in elderly; periodic assessment of treatment need; sexual function inquiry
Special populations	ECG in elderly receiving >10 mg/day or with cardiac risk factors

Brands in India

Nexito® (Sun Pharma)
Cipralex® (Lundbeck India)
Stalopam® (Lupin)
Esetalo® (Abbott)
Rexipra® (Torrent)
Feliz-S® (Torrent)
S-Citadep® (Cipla)
Multiple generic formulations widely available

FDC note: Combinations with clonazepam (e.g., Nexito Plus®, Stalopam Plus®) available — use cautiously; avoid long-term benzodiazepine use

Price range (INR)

Formulation	Approximate Price
Tablets 5 mg	₹3–6 per tablet
Tablets 10 mg	Unidentified
Tablets 20 mg	₹6–12 per tablet
Oral drops 5 mg/mL (15 mL)	₹50–100 per bottle

Note: Not under NLEM 2022 as individual agent. Widely available in government and private sectors.

Clinical pearls

Escitalopram is the S-enantiomer of citalopram — approximately twice as potent; do not substitute 1:1 with citalopram (10 mg escitalopram ≈ 20 mg citalopram)
Lowest drug interaction potential among SSRIs — minimal CYP450 inhibition; preferred when polypharmacy is unavoidable
QT prolongation is dose-dependent — limit to 10 mg/day in elderly and those with cardiac risk factors
Discontinuation syndrome occurs — taper over 2–4 weeks when stopping; symptoms include dizziness, paraesthesias, irritability, insomnia
Sexual dysfunction is common and may persist — discuss proactively; consider dose reduction, drug holidays (weekend breaks — controversial), or switching to bupropion/mirtazapine if problematic
Initial anxiety worsening in panic disorder — start at 5 mg and titrate slowly; short-term benzodiazepine cover may be needed

Version

RxIndia v1.0 — 05 May 2025

Reference

CDSCO approved prescribing information
National Formulary of India (NFI) 2021
Indian Psychiatric Society Practice Guidelines
AIIMS Psychiatry Treatment Protocols
API Textbook of Medicine
NIMHANS Clinical Guidelines
IAP Guidelines (paediatric use)
Published RCTs/meta-analyses (PTSD, PMDD — off-label basis)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...